Subcutaneous Injection of Autologous Adipose Tissue-derived Stromal Vascular Fraction Into the Fingers of Patients With Systemic Sclerosis : Controlled Clinical Trial With Efficacy Assessment

Trial Profile

Subcutaneous Injection of Autologous Adipose Tissue-derived Stromal Vascular Fraction Into the Fingers of Patients With Systemic Sclerosis : Controlled Clinical Trial With Efficacy Assessment

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 22 Jan 2018

At a glance

  • Drugs ECCS 50 (Primary)
  • Indications Systemic scleroderma
  • Focus Registrational; Therapeutic Use
  • Acronyms SCLERADEC II
  • Sponsors Cytori Therapeutics
  • Most Recent Events

    • 22 Jan 2018 According to a Cytori Therapeutics media release, full analysis of the unblinded data set will be performed upon completion of the final patients 6 month follow-up visit, and ata will be available in the second half of 2018
    • 13 Nov 2017 French regulatory authorities approved a 3rd center (Hopital Saint-Louis, Paris) to add to the 2 centers (Assistance Publique Hopitaux de Marseille and CHU de Rouen) for this trial, as reported in a Cytori Therapeutics media release. The Marseille investigators anticipate completing enrollment by the end of 2017.
    • 09 Nov 2017 According to a Cytori Therapeutics media release, status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top